Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$3.94 - $6.27 $8,601 - $13,687
2,183 New
2,183 $13,000
Q4 2022

Jun 14, 2023

BUY
$8.17 - $12.95 $19,501 - $30,911
2,387 New
2,387 $20.8 Million
Q3 2022

Jun 14, 2023

BUY
$11.4 - $17.18 $27,211 - $41,008
2,387 New
2,387 $28.4 Million
Q2 2022

Jun 20, 2023

BUY
$9.23 - $22.43 $22,032 - $53,540
2,387 New
2,387 $34,000
Q2 2022

Mar 30, 2023

BUY
$9.23 - $22.43 $4,338 - $10,542
470 Added 24.52%
2,387 $34,000
Q2 2022

Aug 11, 2022

BUY
$9.23 - $22.43 $4,338 - $10,542
470 Added 24.52%
2,387 $34,000
Q1 2022

Jun 20, 2023

BUY
$14.86 - $23.55 $28,486 - $45,145
1,917 New
1,917 $39,000
Q1 2022

Mar 30, 2023

SELL
$14.86 - $23.55 $92,236 - $146,174
-6,207 Reduced 76.4%
1,917 $39,000
Q1 2022

May 12, 2022

SELL
$14.86 - $23.55 $92,236 - $146,174
-6,207 Reduced 76.4%
1,917 $40,000
Q4 2021

Jun 21, 2023

BUY
$19.99 - $30.24 $162,398 - $245,669
8,124 New
8,124 $187,000
Q3 2021

Jun 21, 2023

BUY
$26.84 - $36.58 $218,048 - $297,175
8,124 New
8,124 $242,000
Q2 2021

Mar 30, 2023

BUY
$28.01 - $36.01 $105,457 - $135,577
3,765 Added 86.37%
8,124 $277,000
Q2 2021

Aug 16, 2021

BUY
$28.01 - $36.01 $227,441 - $292,401
8,120 Added 203000.0%
8,124 $278,000
Q1 2021

Jun 26, 2023

BUY
$30.66 - $49.5 $133,646 - $215,770
4,359 New
4,359 $143 Million
Q1 2021

May 14, 2021

SELL
$30.66 - $49.5 $133,524 - $215,572
-4,355 Reduced 99.91%
4 $143,000
Q4 2020

Jun 22, 2023

BUY
$31.86 - $61.51 $138,877 - $268,122
4,359 New
4,359 $268,000
Q4 2020

Mar 30, 2023

BUY
$31.86 - $61.51 $62,827 - $121,297
1,972 Added 82.61%
4,359 $268,000
Q4 2020

Feb 16, 2021

BUY
$31.86 - $61.51 $138,877 - $268,122
4,359 New
4,359 $268,000

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $73.5M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.